Valuation: StemCell Institute Inc.

Market Cap 7.8B 48.03M 42.01M 38.74M 35.85M 68.04M 4.58B 69.18M 464M 182M 2.25B 180M 176M P/E 2026
49.6x
P/E 2027 * 69.8x
Enterprise Value 7.8B 48.03M 42.01M 38.74M 35.85M 68.04M 4.58B 69.18M 464M 182M 2.25B 180M 176M EV / Sales 2026
2.79x
EV / Sales 2027 * 2.52x
Free-Float
23.41%
Yield 2026 *
-
Yield 2027 * -
1 day+0.40%
1 week+5.26%
Current month+5.11%
1 month+16.36%
6 months-6.85%
Current year-4.04%
1 week 717
Extreme 717
769
1 month 651
Extreme 651
769
Current year 627
Extreme 627
976
1 year 627
Extreme 627
1,245
3 years 627
Extreme 627
3,225
5 years 627
Extreme 627
3,610
10 years 627
Extreme 627
3,610
Manager TitleAgeSince
Director of Finance/CFO - -
President 53 01/06/2016
Director TitleAgeSince
Director/Board Member 66 01/06/2020
Director/Board Member 53 01/09/2013
Director/Board Member 81 01/06/2015
Change 5-day change 1-year change 3-year change Capi.($)
+0.40%+5.26%-18.96%-75.05% 47.75M
-1.80%-1.95%+54.04%+48.04% 133B
-1.46%-1.25%+7.11%+37.06% 91.09B
-0.42%+0.24%-0.14%+71.77% 27.23B
-0.40%-3.88%+19.43%+48.36% 23.05B
-1.75%-1.11%-20.93%-25.61% 20.25B
+0.04%+1.79%+20.98%+150.25% 17.77B
-2.26%-3.80%+59.32%+117.94% 14.81B
+2.08%-2.08%+2.23%+9.64% 14.51B
-0.38%+1.68%-10.69%-3.13% 12.86B
Average -0.60%+2.05%+11.24%+37.93% 35.49B
Weighted average by Cap. -1.28%+1.58%+25.40%+47.45%

Financials

2026 2027 *
Net sales 2.87B 17.68M 15.46M 14.26M 13.19M 25.04M 1.69B 25.46M 171M 66.94M 829M 66.36M 64.92M 3.1B 19.09M 16.7M 15.4M 14.25M 27.05M 1.82B 27.5M 184M 72.31M 895M 71.68M 70.13M
Net income 180M 1.11M 970K 894K 827K 1.57M 106M 1.6M 10.71M 4.2M 51.96M 4.16M 4.07M 110M 677K 593K 547K 506K 960K 64.67M 976K 6.55M 2.57M 31.76M 2.54M 2.49M
Net Debt - -
Logo StemCell Institute Inc.
StemCell Institute Inc is mainly engaged in the cell bank business, which separates and stores cord blood. The Company operates cell bank business from umbilical cord blood and umbilical cord, development of new treatment methods and regenerative medicine products, regenerative medicine and fertility treatment, business development and investment in childbirth and childcare areas. The Company operates Cell Bank business segment. After signing the contract for the separation and storage of umbilical cord blood with customers (pregnant women), the umbilical cord blood collected at domestic umbilical cord blood collection cooperative hospitals (university hospitals, obstetric clinics and others) is collected, and carried into its cell processing center in Minato-ku, Tokyo and Midori-ku, Yokohama. It is stored at its cell storage center (Midori-ku, Yokohama, Kanagawa) for a long time at ultra-low temperature after stem cells contained in cord blood being separated, extracted and prepared.
Employees
117
Date Price Change Volume
09/07/26 ¥761.00 +0.40% 13,800
08/07/26 ¥758.00 -0.39% 5,200
07/07/26 ¥761.00 +2.01% 5,900
06/07/26 ¥746.00 +0.67% 4,800
03/07/26 ¥741.00 +3.06% 15,900

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 7096 Stock